Pharmidex

Pharmidex is a UK-based AAALAC-accredited CRO specializing in translational research and offering a wide range of services in the biotechnology, healthcare, and pharmaceutical industries. Established in 2002, the company's services include drug metabolism and pharmacokinetics (DMPK), bioanalysis, toxicology, histology, clinical chemistry, hematology, and in vitro ADME with a focus on in silico modeling and efficacy models tailored to specific disease programs such as oncology, CNS, respiratory, stroke, autoimmune, and metabolic diseases. With a client base of over 250 global clients, including medical charities, academic groups, biotech, and pharmaceutical companies, Pharmidex has successfully completed more than 15,000 studies. In addition to its fee-for-service offerings, the company actively seeks collaboration opportunities in grant-funded projects and has participated in over 30 collaborative grant-funded projects to date with more than 167 global collaborators. An investor analysis presents an opportunity to gauge the potential of Pharmidex in the growing pharmaceutical research and development sector.